Search

Your search keyword '"Drutel, Guillaume"' showing total 20 results
Start Over Author "Drutel, Guillaume"
20 results on '"Drutel, Guillaume"'

2. Differential expression of the neuronal CB1 cannabinoid receptor in the hippocampus of male Ts65Dn Down syndrome mouse model

Author

Di Franco, Nadia, primary, Drutel, Guillaume, additional, Roullot-Lacarrière, Valérie, additional, Julio-Kalajzic, Francisca, additional, Lalanne, Valérie, additional, Grel, Agnès, additional, Leste-Lasserre, Thierry, additional, Matias, Isabelle, additional, Cannich, Astrid, additional, Gonzales, Delphine, additional, Simon, Vincent, additional, Cota, Daniela, additional, Marsicano, Giovanni, additional, Piazza, Pier Vincenzo, additional, Vallée, Monique, additional, and Revest, Jean-Michel, additional

Published
2022
Full Text
View/download PDF

7. New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type‐1 cannabinoid receptor (CB1R) activity and function.

Author

Raux, Pierre‐Louis, Drutel, Guillaume, Revest, Jean‐Michel, and Vallée, Monique

Subjects
*CANNABINOID receptors, *PREGNENOLONE, *ALLOSTERIC regulation
Abstract

Pregnenolone is a steroid with specific characteristics, being the first steroid to be synthesised from cholesterol at all sites of steroidogenesis, including the brain. For many years, pregnenolone was defined as an inactive precursor of all steroids because no specific target had been discovered. However, over the last decade, it has become a steroid of interest because it has been recognised as being a biomarker for brain‐related disorders through the development of metabolomic approaches and advanced analytical methods. In addition, physiological roles for pregnenolone emerged when specific targets were discovered. In this review, we highlight the discovery of the selective interaction of pregnenolone with the type‐1 cannabinoid receptor (CB1R). After describing the specific characteristic of CB1Rs, we discuss the newly discovered mechanisms of their regulation by pregnenolone. In particular, we describe the action of pregnenolone as a negative allosteric modulator and a specific signalling inhibitor of the CB1R. These particular characteristics of pregnenolone provide a great strategic opportunity for therapeutic development in CB1‐related disorders. Finally, we outline new perspectives using innovative genetic tools for the discovery of original regulatory mechanisms of pregnenolone on CB1‐related functions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements

Author

Durrieu-Gaillard, Stéphanie, primary, Dumay-Odelot, Hélène, additional, Boldina, Galina, additional, Tourasse, Nicolas J., additional, Allard, Delphine, additional, André, Fabrice, additional, Macari, Françoise, additional, Choquet, Armelle, additional, Lagarde, Pauline, additional, Drutel, Guillaume, additional, Leste-Lasserre, Thierry, additional, Petitet, Marion, additional, Lesluyes, Tom, additional, Lartigue-Faustin, Lydia, additional, Dupuy, Jean-William, additional, Chibon, Frédéric, additional, Roeder, Robert G., additional, Joubert, Dominique, additional, Vagner, Stéphan, additional, and Teichmann, Martin, additional

Published
2018
Full Text
View/download PDF

12. 604 PREDICTIVE FACTORS OF IMPAIRED FROZEN KIDNEY TISSUE SAMPLES QUALITY IN THE SETTING OF ROUTINE SURGICAL ACTIVITY

Author

Capon, Grégoire, primary, Donon, Laurence, additional, Soulet, Fabienne, additional, Deminiere, Colette, additional, Merlio, Jean-Philippe, additional, Doussau, Adelaïde, additional, De Pommerol, Marie Jullien, additional, Drutel, Guillaume, additional, Ravaud, Alain, additional, Quemener, Cathy, additional, Robert, Grégoire, additional, Pasticier, Gilles, additional, Ballanger, Philippe, additional, Bikfalvi, Andréas, additional, Ferrière, Jean-Marie, additional, and Bernhard, Jean-Christophe, additional

Published
2013
Full Text
View/download PDF

14. Discovery of Naturally Occurring Splice Variants of the Rat Histamine H3Receptor That Act as Dominant-Negative Isoforms

Author

Bakker, Remko A., primary, Lozada, Adrian Flores, additional, van Marle, André, additional, Shenton, Fiona C., additional, Drutel, Guillaume, additional, Karlstedt, Kaj, additional, Hoffmann, Marcel, additional, Lintunen, Minnamaija, additional, Yamamoto, Yumiko, additional, van Rijn, Richard M., additional, Chazot, Paul L., additional, Panula, Pertti, additional, and Leurs, Rob, additional

Published
2006
Full Text
View/download PDF

19. Discovery of Naturally Occurring Splice Variants of the Rat Histamine H3 Receptor That Act as Dominant-Negative Isoforms

Author

Bakker, Remko A., Lozada, Adrian Flores, van Marle, André, Shenton, Fiona C., Drutel, Guillaume, Karlstedt, Kaj, Hoffmann, Marcel, Lintunen, Minnamaija, Yamamoto, Yumiko, van Rijn, Richard M., Chazot, Paul L., Panula, Pertti, and Leurs, Rob

Abstract

We described previously the cDNA cloning of three functional rat histamine H3 receptor (rH3R) isoforms as well as the differential brain expression patterns of their corresponding mRNAs and signaling properties of the resulting rH3A, rH3B, and rH3C receptor isoforms (Mol Pharmacol 59:1–8). In the current report, we describe the cDNA cloning, mRNA localization in the rat central nervous system, and pharmacological characterization of three additional rH3R splice variants (rH3D, rH3E, and rH3F) that differ from the previously published isoforms in that they result from an additional alternative-splicing event. These new H3R isoforms lack the seventh transmembrane (TM) helix and contain an alternative, putatively extracellular, C terminus (6TM-rH3 isoforms). After heterologous expression in COS-7 cells, radioligand binding or functional responses upon the application of various H3R ligands could not be detected for the 6TM-rH3 isoforms. In contrast to the rH3A receptor (rH3AR), detection of the rH3D isoform using hemagglutinin antibodies revealed that the rH3D isoform remains mainly intracellular. The expression of the rH3D-F splice variants, however, modulates the cell surface expression-levels and subsequent functional responses of the 7TM H3R isoforms. Coexpression of the rH3AR and the rH3D isoforms resulted in the intracellular retention of the rH3AR and reduced rH3AR functionality. Finally, we show that in rat brain, the H3R mRNA expression levels are modulated upon treatment with the convulsant pentylenetetrazole, suggesting that the rH3R isoforms described herein thus represent a novel physiological mechanism for controlling the activity of the histaminergic system.

Published
2006

20. Serotonin 2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons.

Author

Cathala A, Devroye C, Drutel G, Revest JM, Artigas F, and Spampinato U

Subjects
Animals, Dorsal Raphe Nucleus drug effects, GABA-A Receptor Antagonists administration & dosage, GABAergic Neurons drug effects, Injections, Intraventricular, Male, Neural Inhibition drug effects, Pyrimidines administration & dosage, Rats, Rats, Sprague-Dawley, Serotonergic Neurons drug effects, Serotonin metabolism, Serotonin Antagonists administration & dosage, Selective Serotonin Reuptake Inhibitors administration & dosage, gamma-Aminobutyric Acid metabolism, Dorsal Raphe Nucleus metabolism, GABAergic Neurons metabolism, Neural Inhibition physiology, Receptor, Serotonin, 5-HT2B metabolism, Serotonergic Neurons metabolism
Abstract

The central serotonin 2B receptor (5-HT 2B R) is a well-established modulator of dopamine (DA) neuron activity in the rodent brain. Recent studies in rats have shown that the effect of 5-HT 2B R antagonists on accumbal and medial prefrontal cortex (mPFC) DA outflow results from a primary action in the dorsal raphe nucleus (DRN), where they activate 5-HT neurons innervating the mPFC. Although the mechanisms underlying this interaction remain largely unknown, data in the literature suggest the involvement of DRN GABAergic interneurons in the control of 5-HT activity. The present study examined this hypothesis using in vivo (intracerebral microdialysis) and in vitro (immunohistochemistry coupled to reverse transcription-polymerase chain reaction) experimental approaches in rats. Intraperitoneal (0.16 mg/kg) or intra-DRN (1 μM) administration of the selective 5-HT 2B R antagonist RS 127445 increased 5-HT outflow in both the DRN and the mPFC, these effects being prevented by the intra-DRN perfusion of the GABA A antagonist bicuculline (100 μM), as well as by the subcutaneous (0.16 mg/kg) or the intra-DRN (0.1 μM) administration of the selective 5-HT 1A R antagonist WAY 100635. The increase in DRN 5-HT outflow induced by the intra-DRN administration of the selective 5-HT reuptake inhibitor citalopram (0.1 μM) was potentiated by the intra-DRN administration (0.5 μM) of RS 127445 only in the absence of bicuculline perfusion. Finally, in vitro experiments revealed the presence of the 5-HT 2B R mRNA on DRN GABAergic interneurons. Altogether, these results show that, in the rat DRN, 5-HT 2B Rs are located on GABAergic interneurons, and exert a tonic inhibitory control on 5-HT neurons innervating the mPFC., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results